Vancomycin monitoring: One or two serum levels?

Therapeutic Drug Monitoring

Volumn 19, Issue 6, 1997, Pages 614-619

  Andrés, Inés ^a   López, Rosa ^a   Pou, Leonor ^a   Piñol, Francesc ^a   Pascual, Carles ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Bayesian forecasting; Pharmacokinetics; Vancomycin

Indexed keywords

VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BAYES THEOREM; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STEADY STATE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BAYES THEOREM; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 0344863101     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199712000-00002     Document Type: Article

References (21)

1. Pryka RD, Rodvold KA, Erdman SM. An updated comparison of drug dosing methods, IV: Vancomycin. Clin Pharmacokinetic 1991;20:463-76.
2. Edwards DJ, Pancorbo S. Routine monitoring of serum vancomycin concentrations: waiting for proof of its value. Clin Pharm 1987;6:652-4.
3. Rodvold KA, Zokufa H, Rotschafer JC. Routine monitoring of serum vancomycin concentrations: can waiting be justified?. Clin Pharm 1987;6:665-8.
4. Shalansky S. Rationalization of vancomycin serum concentrations monitoring. Can J Hosp Pharm 1995;48:17-24.
5. McLean AJ, Ioannides-Demos LL; Spicer WJ, Christophidis N. Aminoglycoside dosing: one, two or three times a day? Med J Aust 1996;164:39-42.
6. Peetermans WE, Hoogeterp JJ, Hazekamp-Van Dokkum AM, et al. Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrob Agents Chemother 1990;34:1869-74.
7. Ackerman BH, Vannier AM, Eudy EB. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother 1992;36:1766-9.
8. Bouvier d'Yvoire MJY, Maire PH. Dosage regimens of antibacterials: implications of a pharmacokinetic/pharmacodynamic model. Clin Pharmacol 1996;11:229-39.
9. Moellering RC. Monitoring serum vancomycin levels: climbing the mountain because it is there? (editorial). Clin Infect Dis 1994; 18:544-6.
10. Saunders NJ. Why monitoring peak vancomycin concentrations? Lancet 1994;344:1748-50.
11. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
12. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9:503-12.
13. Lazevo LA, Davis RL. Two- versus three-sample method for estimating gentamicin pharmacokinetic values. Am J Hosp Pharm 1994;51:1021-24.
14. Rodvold KA, Gentry CA, Plank GS, Kraus DM, Nickel E, Gross JR. Bayesian forecasting of serum vancomycin concentrations in neonates and infants. Ther Drug Monit 1995;17:239-46.
15. Sheiner LB, Beal SL, Rosenberg B, Marathe VV. Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979;26:294-305.
16. Leader WG, Chandler MHH, Castiglia M. Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet 1995;28: 327-42.
17. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic monitoring: is it necessary? Ann Pharmacother 1993;27: 594-8.
18. Fernandez de Gata MM, Fruns I, Calvo MV, Lanao JM, Dominguez Gil A. Influence of pharmacokinetic model on vancomycin peak concentration targets. Ther Drug Monit 1996;18: 145-8.
19. Marra F, Cairns B, Jewesson P. Vancomycin serum concentration monitoring: the middle ground is best. Clin Drug Invest 1996;12 (2):105-18.
20. Gonzalez Martin G, Acuña V, Perez C, Labarca J, Guevara A, Tagle R. Pharmacokinetics of vancomycin in patients with severely impaired renal function. Int J Clin Pharmacol Ther 1996; 34:71-5.
21. Drusano GL. Human pharmacodynamics of beta-lactams, aminoglycosides and their combination. Scan J Infec Dis 1991;74 (suppl):235-48.